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ABSTRACT 
Background  
One could hypothesize that the biomedical research agenda aligns with the (global) burden of 
disease, since it should aim to reduce illness and death. We investigated the relationship 
between publication volume and Research-dependent Fraction of Global Burden of Disease 
(BoD-RdF): the fraction of Burden of Disease that can only be relieved by further biomedical 
research. Aim of this comparison is to evaluate and support the optimization of biomedical 
research portfolios. 
 
Methods 
BoD-RdF, defined as the burden of disease reported in the 1st quartile of the age corrected 
burden of disease per capita for all countries, was calculated using 2014 Global Burden of 
Disease data from WHO for the years 2000 and 2012. Publication volumes were based on 6.5 
million publications between 2000 and 2012 from the Clarivate Analytics’ Web of Science 
database, categorized into disease groups by keyword analysis and text mining techniques. The 
categorized publication volumes were compared to BoD-RdF.  
 
Findings 
From the global burden of disease in 2012, we estimate that 48% depends on further biomedical 
research to be relieved (BoD-RdF). Generally, diseases with high burden are underresearched, 
whereas diseases with relatively little burden are overrepresented in the global research 
portfolio. Large variations in publication volume (up to twelve-fold) exist for diseases with 
similar BoD-RdF. Likewise, diseases with a similar publication volume vary greatly in BoD-
RdF (up to 50-fold). Compared to 2000, the disease-specific publication volume almost 
doubled in 2012, but the correlation with burden of disease and BoD-RdF showed only a small 
improvement. 
 
Interpretation 
We found a profound and persistent misalignment of publication volume with BoD-RdF. For 
18 diseases, which account for 50% of the global BoD-RdF, a factor 2 increase of the 
publication volume would be justified based on BoD-RdF. This misalignment persisted over 
the last decade, despite doubling of the total number of disease specific publications.  
Although we recognize that the global research portfolio will never be dictated by global 
disease burden alone, we propose that the comparison between BoD-RdF and publication 
volume provides supportive insights that can be used in optimization of the research portfolio. 
 
Funding 
This research received no specific grant from any funding agency in the public, commercial or 
not-for-profit sectors. The authors are solely responsible for study design, data collection and 
analysis, interpretation, and writing of the report. 
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BACKGROUND 
Biomedical research is the broad area of science that aims to find ways to prevent, effectively 
diagnose and treat diseases that cause illness and death in humans. Hence, it might be 
hypothesized that the biomedical research agenda would be based on the (global) burden of 
disease. In other words, diseases with a relatively high burden in terms of morbidity and 
mortality should ideally get proportionately more research. Studying the alignment of burden 
of disease with biomedical research output may contribute to an objective evaluation of the 
current biomedical research portfolio.  
 
We were surprised that, despite the enormous amount of biomedical research and funding, and 
the vast amount of literature on quality of biomedical research on the one hand, and the 
comprehensive WHO study on global burden of disease on the other hand1, little research has 
been published on the relationship between the global disease-specific research portfolio and 
the burden of disease2,3.  
 
Classification of publications to broader disciplines (e.g. neurology, cardiology, surgery) is 
readily available. However, a more incisive analysis can be achieved by analyzing systematic 
classification of diseases according to ICD-10 codes employing MESH terminology or text 
mining techniques and author keywords, as we have recently developed4. Using the latter 
technique, mapping research portfolios (based on research output in publications and citations 
by disease) can be done systematically, on a global, national, and institutional level over time.  
 
The burden of disease for a specific disease can be alleviated in two ways. Firstly, current 
international best practices for prevention, diagnosis, and treatment of a disease can be 
implemented worldwide. Secondly, new scientific insights can improve the current best 
practice disease management strategies and further alleviate burden of disease. For diseases 
with a large variation in burden of disease across countries, such as HIV/AIDS, we hypothesize 
that the global burden of disease could largely – but not entirely – be reduced by implementing 
best practices rather than developing new scientific insights. For diseases with little variation 
in burden of disease between countries, such as depression, we hypothesize that, for improving 
the global burden of disease, new medical breakthroughs are required. When studying the 
alignment of the publication volume and burden of disease between diseases, we need to take 
both these factors into account. Or more specifically, disease burden that could be alleviated 
by implementing existing disease management strategies rather than by new research should 
be excluded when studying alignment with research priorities. 
 
Currently a limited list of amenable diseases, originally developed by Rutstein and colleagues5, 
is widely used as a measure for avoidable burden of disease6. Our goal was to study the burden 
of all diseases in all countries and relate this to disease-specific biomedical research. Therefore, 
we introduce a new measure that we propose to use as a proxy for the burden that can only be 
relieved by further biomedical research: Research-dependent Fraction of Global Burden of 
Disease (BoD-RdF). We believe that our analysis of the relationship between BoD-RdF and 
the volume of disease-specific research7 can contribute to better alignment of biomedical 
research portfolios.  
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METHOD 
Burden of Disease  
We used data from the 2014 Global Burden of Disease study for all diseases in all countries1. 
The same source was used for the number of inhabitants and age distribution per country. We 
expressed burden of disease as DALYs per 1000 capita to correct total burden for differences 
in population size. We used data on burden of disease and publication volume per disease for 
both 2000 and 2012.  
 
Research-dependent Fraction of Global Burden of Disease  
The BoD-RdF represents the fraction of a disease’s total burden of disease that can only be 
relieved by further biomedical research. For diseases with a high variation in burden per capita 
between countries, the BoD-RdF is low. Alleviation of most of the burden requires 
implementation of best practices rather than new biomedical research. For diseases with little 
variation across countries, the BoD-RdF is high and further biomedical research plays an 
important role in alleviating the global burden. Burden of disease per capita per country should 
be age corrected for fair comparison. The variation in Burden of disease per capita between 
countries for age specific diseases such as dementia is highly dependent on a country’s age 
distribution. Therefore, we defined BoD-RdF as the burden of disease reported of the 1st 
quartile of the age corrected burden of disease by country. 
 
For example, the age corrected burden of disease for diabetes mellitus, ranges between 
countries from 2.4 DALY’s per 1000 capita in the UK to 48.5 in Mauritius. The burden reported 
in the 1st quartile (6.3 DALY’s per 1000 capita) is the BoD-RdF for diabetes mellitus. The 1st 
quartile was chosen because it reflects an international best practice exhibited by several 
countries, whereas the lowest possible burden might reflect a statistical outlier. While this 
definition is arbitrary and other, more sophisticated, approaches may be better; it intuitively 
distinguishes between what can be achieved with current knowledge and where further 
knowledge is needed.  
 
Disease specific publication volume  
Publication volumes for biomedical research were based on Clarivate Analytics’ Web of 
Science database7 (WoS) as available at the Centre for Science and Technology Studies 
(CWTS) of Leiden University. We included biomedical research fields only and compiled a 
dataset with 6.5 million publications, published between 2000 and early 2014. Using text 
mining techniques and analysis of keywords, publications were linked to 269 disease groups. 
This method and its validation is described in detail elsewhere4.  
 
Correlations between burden and publication volume were calculated using the R2-method 
based on a simple linear regression analysis with BoD-RdF as the dependent variable.  
 
FINDINGS 
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Research dependent fraction of global burden is 48% of global burden of disease, but 
varies greatly between diseases  
Table 1 provides the number of publications, global burden of disease and BoD-RdF per 
disease for both 2000 and 2012.  
 
[TABLE 1] 
 
48% of the global burden of disease is BoD-RdF. The share of BoD-RdF in the global burden 
of disease varies widely between diseases. As illustrated in Figure 1 for the 25 diseases that 
cause the most burden worldwide, the BoD-RdF varies between 2.2% for HIV-AIDS and 
99.6% for depression.  
 
[FIGURE 1]  
 
Biomedical research volume is correlated to BoD-RdF with large variation between 
diseases 
Generally, diseases with higher BoD-RdF have a higher volume of global research output 
(R2=0.431, Figure 2A). There is a large variation between diseases. Compared to a theoretical 
direct proportionality between BoD-RdF and publication volume, many diseases with high 
BoD-RdF are relatively underresearched (indicated in green in Table 1 and Figure 2A), 
whereas other diseases with relatively low BoD-RdF are overrepresented in the global disease-
specific research portfolio (indicated in blue in Table 1 and Figure 2A), giving a weak linear 
correlation (see Figure 2A and data in Table 1).  
 
[FIGURE 2] 
 
Comparing publication volume to global burden of disease instead of BoD-RdF gives a similar 
correlation (R2=0.433, data in Table 1).  
 
 
As shown in Table 1, there are big differences between the share in research output and the 
share in burden of disease for specific diseases. The data from Table 1 is illustrated in Figure 
2B to highlight these large differences.  For example, diabetes and back and neck pain have a 
similar BoD-RdF (2.15% and 1.96% of the total global BoD-RdF, respectively), but the 
publication volume on diabetes is twelvefold higher than back and neck pain (3.77% versus 
0.30%, respectively). Similarly, ‘melanoma and other skin cancers’ has a comparable 
publication volume to lower respiratory infections (1.01% and 0.86% of the global publication 
volume, respectively) but causes a much lower global burden (0.10% versus 5.36%). 
  
To understand if this mismatch reflects different cultures between biomedical disciplines, like 
publishing a single comprehensive paper or multiple papers on a single scientific finding, we 
delve deeper into a single discipline. We find that this mismatch is also present within 
biomedical disciplines, such as in the well-researched discipline of oncology. Within oncology 
certain cancers are overresearched and others underresearched in relation to their global BoD-
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RdF. For example, breast cancer, lymphoid cancers, colorectal cancer, liver cancer and stomach 
cancer cause a similar BoD-RdF (between 2.47 and 2.98 DALYs per 1000 capita worldwide 
in 2012), as illustrated in Figure 2C. The publications volumes for these diseases however 
differ 7-fold. Similarly, the publication volume for melanoma, prostate cancer, colon cancer 
and lung cancer is similar (between approximately 5000 and 6200 publications in 2012), but 
their burden varies 15-fold.  
 
 
Research portfolio is slightly better aligned to BoD-RdF in 2012 than in 2000  
The 2012 BoD-RdF and publication volume show a similar pattern to that in 2000 (see Table 
1). The correlation of Bod-RdF and publication volume was slightly better in 2012 (R2=0.431) 
than in 2000  (R2=0.367). The disease-specific research volume doubled between 2000 and 
2012 from approximately 275 000 to 550 000 publications, while the BoD-RdF has marginally 
declined from 200 to 185 DALYs per 1000 capita in the same period. The diseases that account 
for a high publication volume in 2012 are largely the same as in 2000.  
In general, the share in publication volume changed in line with the share of BoD-RdF for 
most diseases. However, for some diseases an opposite trend was observed. For example, 
neonatal conditions and tuberculosis decreased in share of BoD-RdF, -1.44 and -0.20 
percentage point respectively, while their share in publication volume increased, +0.22 and 
+0.09 percentage point. Conversely, HIV/AIDS and hypertensive heart disease increased in 
share of BoD-RdF, +0.03 and +0.09 percentage point respectively, while their share in 
publication volume decreased, -0.33 and -0.15 percentage point. 
 
INTERPRETATION 
Our results show that BoD-RdF is not a strong driver for publication volume catalogued by 
disease. There is a weak correlation, and the misalignment is profound. For 18 diseases, a 
doubling in the current research volume is justified based on their burden (see green triangles 
in Figure 2A). These 18 diseases together account for more than 50% of the total global burden 
of disease. For Migraine and headache, hyperplasia of the prostate, osteoarthritis, back and 
neck pain, and other congenital anomalies (marked bold in Table 1), a fourfold increase in 
publications is required to bring the research volume in line with BoD-RdF. For 28 diseases 
the 2012 publication volume could be halved if we base our research portfolio on BoD-RdF 
alone (see red dots in Figure 2A). These 28 diseases account for 18% of the total global burden 
of disease.  
 
The misalignment is persistent over the last decade and is therefore likely to persist in the near 
future if not actively corrected. We conclude that despite almost doubling of the research 
volume in the period 2000-2012, the pattern of overresearched and underresearched diseases 
has remained essentially the same. Our analysis provides policy makers, funding organizations, 
as well as researchers a quantitative source of information for realigning biomedical research 
priorities with the goal to alleviate burden of disease.  
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If priorities in research were based on BoD-RdF alone, one would have greater impact in 
reducing global burden. Here we assume that volume of publication ultimately drives reduction 
in burden of disease. We have no direct proof of this, but it seems reasonable to expect that 
more research would eventually lower research dependent burden. We also assume that we can 
work with publication volume rather than research effort and funding. We have not shown that 
additional funding or effort results in more publications, though again this seems reasonable. 
Other studies have explored the match between funding and burden of disease, albeit with a 
narrower focus on NIH funding alone5. 
 
To derive a better research portfolio, we draw a theoretical linear reference line where the 
publication volume is directly proportional to BoD-RdF (a forced fit through (0,0) and (1,1) 
coordinates: see blue line in Figure 2A). Deviation from the line represents the extent to which 
a disease area is over- or underresearched compared to its BoD-RdF. In a ‘zero sum game’ 
exercise, where the total publication volume remains constant, we could shift the research focus 
and thus publication volume from overresearched diseases where publication volume is 
relatively high in relation to BoD-RdF, to underresearched diseases where the opposite is the 
case.  Of the approximate total of 550 000 publications we attributed to diseases in 2012, we 
find that ~400 000 publications focus on overresearched diseases and ~150 000 cover 
underresearched diseases.  In Table 1, the major diseases which are overresearched are 
highlighted in blue, whereas the green colored diseases merit more research.  
 
A publication volume portfolio driven solely by BoD-RdF would be certainly different from 
what we had in 2012. Diseases like back and neck pain, migraine and headache, and 
osteoarthritis would deserve 5 to 12 times more publications than the 2012 volume, while 
infertility and multiple sclerosis could do with a much lower volume –half the 2012 publication 
volume. This mismatch can be found within every discipline.  
 
Of course, there are limitations to our study: 
1. Disease burden in certain disease areas can partly be eradicated by applying existing 
biomedical knowledge. For this part of the burden, more research is not needed but 
rather implementation of best practices is required. We have tried to correct for this 
effect in our methodology, by using BoD-RdF instead of burden of disease, but this is 
an approximation.  
2. Classifying ~6.5 millions publications and linking these to 269 disease areas will 
inevitably contain inaccuracies, even though we validated the linking methodology 
thoroughly4, we cannot be sure how this may influence these results.  
3. Not all fundamental research publications that may have contributed to alleviating 
burden of disease can be attributed to specific diseases. This could introduce a bias in 
the attribution of publications to diseases.  
 
Taking these limitations into consideration, there are several other factors that may explain the 
observed misalignment between biomedical publication volume and burden of disease.  
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1. The research portfolio is driven by many other factors than burden of disease, like 
political and funding priorities, commercial opportunities, geographical or individual 
preferences, and leading trends in research8,9,10.  
2. The impact of research on reducing burden of disease may vary between diseases. 
Diseases likely have different relations of research effort vs. burden of disease 
reduction. Some diseases may therefore require more research efforts to achieve the 
same reduction in burden. Studying longer timelines and trying to account for multiple 
factors in a multivariate analysis could provide insights in these differences, potentially 
uncovering in which disease areas biomedical publications contribute less to better 
health. This could be a useful, albeit challenging, avenue of future research. 
3. The time lag between research initiation and publication may be significantly different 
from the burden of disease progression for the same disease, resulting in the observed 
mismatch. Burden of a disease may increase or decrease unpredictably, for example 
due to epidemics, changes in lifestyle, age distribution and medical breakthroughs, 
resulting in research misalignment. This effect could be assessed by epidemiological 
studies and can be incorporated in designing research priorities. 
4. The geographical mismatch between research (mainly developed countries) and burden 
(mainly developing countries) could also partially explain the observed mismatch 
between global BoD-RdF and global publication volume. We undertook country 
specific analyses (not presented here) and found that similar levels of mismatch exist 
at a country level as we report here at a global level, though not for all countries. 
 
While recognizing the limitations and potential explanations, we believe that the comparison 
between BoD-RdF and publication volume is a relevant metric that can already be used to 
support better alignment of the biomedical research portfolio. Although we cannot quantify 
how much extra reduction in DALY is possible if we realign the research portfolio, we can be 
confident that for certain disease areas more research is justified and can be undertaken by 
shifting the priorities between diseases.  
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Research in Context 
 
Evidence before this study 
Studies on both burden of disease and research portfolios by disease classification are of recent 
origin. Most of the work emerged at the end of last century. The Global Burden of Diseases, 
Injuries and Risk Factors study today is a comprehensive study of 195 countries and territories 
from 1995-2015. The value and limitations of the GBD-study are well documented elsewhere 
11–14. More recent work builds on the opportunities such a comprehensive database provides.   
A recent study by Murray and colleagues15 combines the GBD data with amenable mortality 
studies to develop a composite healthcare access and quality index for all countries. This study 
presents frontiers for 32 disease areas and for all countries. Amenable mortality is a useful 
concept with a longer history of study dating from Rutstein and colleagues in the 1970s5 to a 
recent review by Nolte and McKee6. By its very nature such an approach is limited. We are not 
aware of any comprehensive study that includes all diseases, and even if there is agreement on 
a definition of amenability of mortality, it is a constantly changing target. Nolte and McKee 
acknowledge these limitations in their review and caution against use of this definition for 
comparative purposes. Through its frontier analysis, the work of Murray and colleagues 
provides a more robust and comprehensive approach to amenability but it is limited to the 32 
causes amenable to treatment.  
Literature is more limited on classification, quantification and qualification of biomedical 
research output, or deciphering research portfolios. We are aware of three studies. Two of these 
use NIH funding in the USA per disease area. Gross and colleagues8 were the first to publish 
the link between NIH funding (1996) and burden of disease (1994) and Gillum and colleagues 
updated their work to 2004-20069. Both found that burden of disease is a predictor of funding 
though there were large outliers. These studies are limited to the USA and to a single albeit 
major funding source, the NIH. Furthermore, the authors acknowledge that the NIH funding 
mapping to diseases is not standardized and its reliability is unknown. Nonetheless the authors 
found that in the ten-year period between the two studies the alignment between funding and 
burden of disease had not improved. 
A study by Evans and colleagues reports a methodology to link publications to diseases and to 
compare publication volume to burden of disease2. This study comes closest to our own work 
here, though the focus of the study is on the mismatch between the burden and health 
knowledge in developing and developed countries. Although Evans et al. use burden of disease, 
they do not split it in an ‘amenable’ and ‘unamenable’ component.  
 
Added value of this research 
The research we present is novel in several ways. Other than Evans and colleagues this is the 
first reported study that links all Web of Science biomedical publications (2.5 million) to a 
comprehensive and detailed disease classification based on ICD-10 (269). We have used two 
base years 2000 and 2012, a much longer and recent period than reported so far.  
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Importantly, we have used the observed variation in burden of diseases across nations in the 
GBD study to split the burden in a medically ‘amenable’ and an ‘unamenable’ component 
(BoD-RdF). This allows us to correct for areas where the publication volume appears to be too 
low given the burden while most likely more biomedical research will not have much effect on 
the burden. 
To our knowledge this study is unique both in comprehensiveness and systematic approach and 
in its use of the country variation to identify the BoD-RdF. 
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TABLES AND FIGURES 
Table 1: Global publications, burden of disease, and BoD-RdF for a set of 77 diseases/causes 
in 2000 and 2012, and the share of BoD-RdF of the total burden of disease and share of BoD-
RdF divided by the share of publications in 2012. 
 
  
2000 2012
ICD-10 chapter Disease/cause
 Publications 
[# (% of total)] 
Burden of disease
[DALYs per 1000 
capita (% of total)]
BoD-RdF  
[DALYs per 1000 
capita (% of total)]
 Publications 
[# (% of total)] 
Burden of disease
[DALYs per 1000 
capita (% of total)]
BoD-RdF  
[DALYs per 1000 
capita (% of total)]
Share of BoD-RdF of 
burden of disease
Share of BoD-RdF 
divided by share of 
publications 
All diseases/causes 273 614 (100.00%) 469.69 (100.00%) 200.15 (100.00%) 534 514 (100.00%) 388.00 (100.00%) 185.09 (100.00%) 48% 1.00                              
Infectious and parasitic diseases Tuberculosis 1 782 (0.65%) 9.90 (2.11%) 1.01 (0.51%) 3 968 (0.74%) 6.19 (1.60%) 0.57 (0.31%) 9% 0.41                              
STDs excluding HIV 1 070 (0.39%) 2.26 (0.48%) 0.49 (0.25%) 1 675 (0.31%) 1.41 (0.36%) 0.44 (0.24%) 31% 0.75                              
HIV/AIDS 6 538 (2.39%) 16.68 (3.55%) 0.25 (0.12%) 10 998 (2.06%) 13.05 (3.36%) 0.29 (0.15%) 2% 0.07                              
Gastro-enteritis 2 726 (1.00%) 27.39 (5.83%) 1.70 (0.85%) 4 387 (0.82%) 14.90 (3.84%) 1.31 (0.71%) 9% 0.87                              
Meningitis/encephalitis 1 818 (0.66%) 8.23 (1.75%) 0.92 (0.46%) 3 089 (0.58%) 5.05 (1.30%) 0.57 (0.31%) 11% 0.53                              
Hepatitis 3 542 (1.29%) 1.13 (0.24%) 0.14 (0.07%) 6 589 (1.23%) 1.09 (0.28%) 0.14 (0.08%) 13% 0.06                              
Other infectious diseases 19 941 (7.29%) 35.68 (7.60%) 1.95 (0.97%) 35 146 (6.58%) 19.68 (5.07%) 1.71 (0.92%) 9% 0.14                              
Respiratory infections Lower respiratory infections 2 464 (0.90%) 34.15 (7.27%) 5.37 (2.68%) 4 612 (0.86%) 20.82 (5.37%) 4.40 (2.37%) 21% 2.75                              
Upper respiratory infections  478 (0.17%) 0.33 (0.07%) 0.29 (0.15%)  852 (0.16%) 0.29 (0.08%) 0.26 (0.14%) 90% 0.89                              
Otitis media  572 (0.21%) 0.79 (0.17%) 0.57 (0.29%)  755 (0.14%) 0.74 (0.19%) 0.53 (0.29%) 72% 2.04                              
Maternal conditions Maternal conditions 6 486 (2.37%) 4.58 (0.97%) 0.23 (0.11%) 12 516 (2.34%) 2.85 (0.73%) 0.19 (0.10%) 7% 0.04                              
Neonatal conditions Neonatal conditions 2 645 (0.97%) 48.10 (10.24%) 10.45 (5.22%) 6 322 (1.18%) 33.61 (8.66%) 6.99 (3.78%) 21% 3.19                              
Nutritional deficiencies Malnutrition  979 (0.36%) 7.01 (1.49%) 0.88 (0.44%) 2 052 (0.38%) 4.89 (1.26%) 0.70 (0.38%) 14% 0.99                              
Iron-deficiency anaemia 7 238 (2.65%) 7.65 (1.63%) 3.77 (1.88%) 8 971 (1.68%) 6.75 (1.74%) 3.43 (1.85%) 51% 1.10                              
Malignant neoplasms Mouth and oropharynx cancers 1 217 (0.44%) 1.20 (0.26%) 0.54 (0.27%) 2 953 (0.55%) 1.34 (0.35%) 0.56 (0.30%) 41% 0.54                              
Oesophagus cancer  353 (0.13%) 1.46 (0.31%) 0.36 (0.18%) 1 021 (0.19%) 1.45 (0.37%) 0.33 (0.18%) 22% 0.92                              
Stomach cancer  703 (0.26%) 2.92 (0.62%) 1.11 (0.55%) 1 799 (0.34%) 2.60 (0.67%) 0.94 (0.51%) 36% 1.51                              
Colon and rectum cancers 2 228 (0.81%) 2.30 (0.49%) 1.15 (0.58%) 5 243 (0.98%) 2.47 (0.64%) 1.30 (0.70%) 53% 0.72                              
Liver cancer 1 024 (0.37%) 2.87 (0.61%) 0.85 (0.43%) 2 898 (0.54%) 2.98 (0.77%) 0.98 (0.53%) 33% 0.98                              
Pancreas cancer  743 (0.27%) 0.91 (0.19%) 0.37 (0.18%) 2 047 (0.38%) 1.09 (0.28%) 0.43 (0.23%) 40% 0.61                              
Trachea, bronchus, lung cancers 2 345 (0.86%) 4.92 (1.05%) 1.15 (0.57%) 6 179 (1.16%) 5.44 (1.40%) 1.25 (0.68%) 23% 0.59                              
Melanoma and other skin cancers 2 915 (1.07%) 0.33 (0.07%) 0.25 (0.13%) 5 416 (1.01%) 0.37 (0.10%) 0.26 (0.14%) 69% 0.14                              
Breast cancer 4 929 (1.80%) 2.40 (0.51%) 1.82 (0.91%) 11 814 (2.21%) 2.51 (0.65%) 1.97 (1.07%) 79% 0.48                              
Cervix uteri cancer 1 615 (0.59%) 1.31 (0.28%) 0.66 (0.33%) 3 601 (0.67%) 1.30 (0.34%) 0.56 (0.30%) 43% 0.45                              
Corpus uteri cancer  502 (0.18%) 0.28 (0.06%) 0.18 (0.09%) 1 035 (0.19%) 0.30 (0.08%) 0.16 (0.09%) 54% 0.45                              
Ovary cancer  749 (0.27%) 0.61 (0.13%) 0.43 (0.21%) 1 550 (0.29%) 0.64 (0.17%) 0.53 (0.28%) 82% 0.98                              
Prostate cancer 2 017 (0.74%) 0.72 (0.15%) 0.56 (0.28%) 4 932 (0.92%) 0.83 (0.21%) 0.78 (0.42%) 94% 0.45                              
Bladder cancer  625 (0.23%) 0.48 (0.10%) 0.28 (0.14%) 1 184 (0.22%) 0.50 (0.13%) 0.29 (0.15%) 57% 0.70                              
Lymphomas, multiple myeloma, leukemia 6 152 (2.25%) 3.08 (0.66%) 2.33 (1.16%) 10 112 (1.89%) 2.79 (0.72%) 2.14 (1.15%) 77% 0.61                              
Other malignant neoplasms 8 006 (2.93%) 4.69 (1.00%) 4.21 (2.10%) 16 056 (3.00%) 5.00 (1.29%) 4.28 (2.31%) 86% 0.77                              
Other neoplasms 2 378 (0.87%) 0.69 (0.15%) 0.43 (0.21%) 3 992 (0.75%) 0.74 (0.19%) 0.45 (0.24%) 61% 0.33                              
Diabetes mellitus Diabetes mellitus 6 605 (2.41%) 7.16 (1.53%) 5.86 (2.93%) 20 233 (3.79%) 8.35 (2.15%) 6.28 (3.39%) 75% 0.90                              
Endocrine, blood, immune disorders Endocrine, blood, immune disorders 15 529 (5.68%) 3.59 (0.76%) 2.43 (1.21%) 29 518 (5.52%) 3.88 (1.00%) 2.33 (1.26%) 60% 0.23                              
Mental and behavioral disorders Depression 6 230 (2.28%) 12.31 (2.62%) 12.71 (6.35%) 14 523 (2.72%) 12.69 (3.27%) 12.64 (6.83%) 100% 2.51                              
Schizophrenia 2 361 (0.86%) 1.91 (0.41%) 1.61 (0.80%) 4 693 (0.88%) 1.99 (0.51%) 1.69 (0.92%) 85% 1.04                              
Addiction 1 105 (0.40%) 6.66 (1.42%) 3.54 (1.77%) 2 993 (0.56%) 6.69 (1.72%) 3.68 (1.99%) 55% 3.55                              
Anxiety disorders 1 656 (0.61%) 3.80 (0.81%) 3.97 (1.98%) 4 588 (0.86%) 3.89 (1.00%) 3.81 (2.06%) 98% 2.40                              
Pervasive developmental disorders 1 857 (0.68%) 1.11 (0.24%) 1.07 (0.53%) 6 499 (1.22%) 1.11 (0.29%) 1.06 (0.57%) 96% 0.47                              
Psychosocial disorders 3 511 (1.28%) 1.50 (0.32%) 1.43 (0.72%) 8 267 (1.55%) 1.43 (0.37%) 1.34 (0.72%) 93% 0.47                              
Idiopathic intellectual disability  943 (0.34%) 0.57 (0.12%) 0.33 (0.17%) 1 241 (0.23%) 0.46 (0.12%) 0.28 (0.15%) 61% 0.65                              
Neurological conditions Alzheimer's disease and other dementias 3 279 (1.20%) 1.80 (0.38%) 1.19 (0.59%) 7 367 (1.38%) 2.57 (0.66%) 1.46 (0.79%) 57% 0.57                              
Parkinson's disease 2 257 (0.82%) 0.27 (0.06%) 0.19 (0.09%) 4 131 (0.77%) 0.35 (0.09%) 0.22 (0.12%) 64% 0.16                              
Epilepsy 2 773 (1.01%) 2.91 (0.62%) 1.72 (0.86%) 4 415 (0.83%) 2.92 (0.75%) 1.62 (0.88%) 56% 1.06                              
Multiple sclerosis 1 464 (0.54%) 0.17 (0.04%) 0.09 (0.05%) 3 138 (0.59%) 0.16 (0.04%) 0.10 (0.05%) 61% 0.09                              
Migraine and headache  861 (0.31%) 2.78 (0.59%) 2.46 (1.23%) 1 427 (0.27%) 2.88 (0.74%) 2.48 (1.34%) 86% 5.02                             
Other neurological conditions 9 637 (3.52%) 1.93 (0.41%) 1.31 (0.66%) 19 510 (3.65%) 2.35 (0.61%) 1.37 (0.74%) 58% 0.20                              
Sense organ diseases Sense organ diseases 7 840 (2.87%) 7.43 (1.58%) 5.10 (2.55%) 14 608 (2.73%) 7.47 (1.93%) 5.16 (2.79%) 69% 1.02                              
Cardiovascular diseases Rheumatic heart disease 3 246 (1.19%) 2.34 (0.50%) 0.66 (0.33%) 6 049 (1.13%) 1.69 (0.44%) 0.46 (0.25%) 27% 0.22                              
Hypertensive heart disease 3 418 (1.25%) 3.15 (0.67%) 1.95 (0.97%) 5 869 (1.10%) 3.31 (0.85%) 1.98 (1.07%) 60% 0.97                              
Ischaemic heart disease 7 241 (2.65%) 23.26 (4.95%) 16.25 (8.12%) 13 381 (2.50%) 23.46 (6.05%) 14.20 (7.67%) 61% 3.06                              
Stroke 3 400 (1.24%) 20.45 (4.35%) 11.07 (5.53%) 6 857 (1.28%) 19.99 (5.15%) 9.02 (4.87%) 45% 3.80                              
Cardiomyopathy, myocarditis, endocarditis 3 432 (1.25%) 2.21 (0.47%) 1.24 (0.62%) 7 419 (1.39%) 2.07 (0.53%) 1.24 (0.67%) 60% 0.48                              
Other circulatory diseases 12 655 (4.63%) 6.28 (1.34%) 4.27 (2.13%) 22 757 (4.26%) 5.20 (1.34%) 4.24 (2.29%) 82% 0.54                              
Respiratory diseases Asthma-COPD 3 650 (1.33%) 18.60 (3.96%) 9.49 (4.74%) 6 973 (1.30%) 16.65 (4.29%) 8.94 (4.83%) 54% 3.70                              
Other respiratory diseases 7 298 (2.67%) 3.06 (0.65%) 1.72 (0.86%) 11 522 (2.16%) 2.76 (0.71%) 1.56 (0.84%) 56% 0.39                              
Digestive diseases Peptic ulcer disease 1 748 (0.64%) 1.77 (0.38%) 0.51 (0.25%) 2 053 (0.38%) 1.15 (0.30%) 0.35 (0.19%) 31% 0.50                              
Cirrhosis of the liver 1 588 (0.58%) 5.31 (1.13%) 2.46 (1.23%) 3 593 (0.67%) 5.08 (1.31%) 2.38 (1.28%) 47% 1.91                              
Appendicitis  232 (0.08%) 0.35 (0.07%) 0.09 (0.05%)  414 (0.08%) 0.27 (0.07%) 0.06 (0.03%) 23% 0.43                              
Other digestive diseases 6 399 (2.34%) 4.74 (1.01%) 3.00 (1.50%) 12 851 (2.40%) 4.52 (1.16%) 2.79 (1.51%) 62% 0.63                              
Genitourinary diseases Kidney diseases 4 762 (1.74%) 4.42 (0.94%) 2.15 (1.08%) 10 028 (1.88%) 4.18 (1.08%) 2.19 (1.18%) 52% 0.63                              
Hyperplasia of prostate  208 (0.08%) 0.67 (0.14%) 0.56 (0.28%)  374 (0.07%) 0.77 (0.20%) 0.63 (0.34%) 82% 4.86                             
Urolithiasis  287 (0.10%) 0.21 (0.04%) 0.11 (0.05%)  551 (0.10%) 0.22 (0.06%) 0.11 (0.06%) 51% 0.60                              
Other genitourinary diseases 2 226 (0.81%) 0.83 (0.18%) 0.35 (0.17%) 4 155 (0.78%) 1.11 (0.29%) 0.45 (0.24%) 40% 0.31                              
Infertility 2 390 (0.87%) 0.20 (0.04%) 0.14 (0.07%) 4 416 (0.83%) 0.20 (0.05%) 0.14 (0.08%) 69% 0.09                              
Gynecological diseases  685 (0.25%) 1.48 (0.32%) 1.22 (0.61%) 1 589 (0.30%) 1.49 (0.38%) 1.27 (0.68%) 85% 2.30                              
Skin diseases Skin diseases 5 101 (1.86%) 2.79 (0.59%) 2.10 (1.05%) 8 625 (1.61%) 2.72 (0.70%) 2.10 (1.14%) 77% 0.70                              
Musculoskeletal diseases Arthritis 2 778 (1.02%) 0.74 (0.16%) 0.63 (0.31%) 6 073 (1.14%) 0.82 (0.21%) 0.70 (0.38%) 86% 0.33                              
Osteoarthritis  253 (0.09%) 2.20 (0.47%) 2.08 (1.04%)  869 (0.16%) 2.56 (0.66%) 2.37 (1.28%) 92% 7.87                             
Back and neck pain  715 (0.26%) 7.21 (1.54%) 6.47 (3.23%) 1 619 (0.30%) 7.62 (1.96%) 6.84 (3.69%) 90% 12.19                           
Other musculoskeletal disorders 13 841 (5.06%) 4.30 (0.92%) 4.02 (2.01%) 25 178 (4.71%) 4.75 (1.22%) 4.41 (2.38%) 93% 0.51                              
Congenital anomalies Neural tube defects 3 273 (1.20%) 1.73 (0.37%) 0.36 (0.18%) 4 351 (0.81%) 1.22 (0.31%) 0.19 (0.10%) 16% 0.13                              
Cleft lip and cleft palate  279 (0.10%) 0.13 (0.03%) 0.04 (0.02%)  589 (0.11%) 0.09 (0.02%) 0.04 (0.02%) 39% 0.18                              
Down's syndrome  186 (0.07%) 0.44 (0.09%) 0.38 (0.19%)  324 (0.06%) 0.38 (0.10%) 0.34 (0.18%) 88% 2.99                              
Congenital heart anomalies 1 264 (0.46%) 3.32 (0.71%) 2.16 (1.08%) 2 370 (0.44%) 2.80 (0.72%) 1.89 (1.02%) 68% 2.31                              
Other congenital anomalies  389 (0.14%) 2.96 (0.63%) 2.27 (1.13%)  814 (0.15%) 2.56 (0.66%) 1.73 (0.94%) 68% 6.15                             
Oral conditions Oral conditions 1 858 (0.68%) 2.25 (0.48%) 1.98 (0.99%) 4 030 (0.75%) 2.22 (0.57%) 1.90 (1.02%) 85% 1.36                              
Injuries Injuries 14 127 (5.16%) 51.33 (10.93%) 30.74 (15.36%) 27 907 (5.22%) 43.25 (11.15%) 26.31 (14.22%) 61% 2.72                              
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Figure 1: Burden of disease and the research dependent fraction of burden of disease (BoD-
RdF). The figures show the age-corrected burden per country: regional burden of disease by 
age-group projected on the global age-distribution. (A) Burden of the 25 diseases causing most 
burden of disease globally (B) Burden of depression by country (C) Burden of HIV/AIDS by 
country.   
 
 
Figure 2: Share of BoD-RdF versus share of biomedical publications by disease in 2012. (A) 
All 77 causes/diseases (B) Illustrative selection of specific diseases with comparable 
publication volume but very different BoD-RdF (melanoma and lower respiratory infections) 
and diseases with comparable BoD-RdF but very different publication volumes (diabetes 
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mellitus and back and neck pain) (C) Illustrative selection of specific cancers with comparable 
BoD-RdF but a large variation in publication volume. 
